Seattle Flow Your front door to Seattle's startup scene.
Sign in
Stream Events Podcasts Videos Communities
Taylor Soper / GeekWire

Seattle Biotech OncoResponse Raises $40.6M Series C to Develop Antibody-Based Cancer Treatments

Seattle biotech OncoResponse raised $40.6 million in a Series C round to develop antibody-based cancer immunotherapies, leveraging antibodies from patients with strong immunotherapy responses. Led by CEO Clifford Stocks, the company has now raised nearly $110 million since its 2015 launch.

RRodeo Therapeutics
  • Link
  • Report this item
Replying to

No comments yet.

Seattle Flow — Your front door to Seattle's startup scene.

Run by Marcelo Calbucci MC
Send us a link Terms of Service Privacy For AI assistants
© 2026 Seattle Flow. All rights reserved.

Who liked this

Edit history

Seattle Flow

Your front door to Seattle's startup scene.

Seattle's startup scene is scattered across a hundred feeds, newsletters, and calendars. Seattle Flow brings it together: the news, events, podcasts, and people, plus what the community is saying about them. Every link sends you to the source.

Writing about a Seattle founder, fund, or startup? We'll help it get seen. Found a great story we missed? Send it in.

We're in beta and building this with the community. Tell us what you want to see here.

Seattle's startup scene, every day. The news, events, podcasts, and people, plus what everyone's saying about them. We're in beta: send us a story or tell us what you want to see.